Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AcelRx reports results from phase II clinical study of sufentanil in postoperative pain

Dec. 12, 2008

Phosphagenics presents phase I clinical results for transdermal lidocaine

Dec. 12, 2008

Sosei reports positive results from two phase I trials of SD-118 for neuropathic pain

Dec. 11, 2008

New therapeutic agents for AD and other neurological disorders reported in recent patents

Dec. 11, 2008

Novel analgesic agents reported in recent patent literature

Dec. 11, 2008

AstraZeneca and Targacept present top-line results from phase IIb AZD-3480 trial

Dec. 10, 2008

AC Immune selected as Technology Pioneer 2009 and advances AD program

Dec. 10, 2008

Maas Biolab's intrathecal ciclosporin advances to phase II for ALS treatment

Dec. 10, 2008

Bayer's PDE9 inhibitor improves memory deficits in animal models

Dec. 10, 2008

Recent Takeda patent describes new agents for sleep disorders

Dec. 9, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....
BIO 2026: Alternatives to funding orphan drugs
BioWorld
At the BIO International Convention, nonprofit and for-profit companies discussed ways to fund orphan drug development, especially for ultra-rare diseases where...
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...